Summary
Pfizer Inc. reported strong revenue growth of 47% to $12.49 billion for the first quarter of 2004 compared to the same period in 2003, primarily driven by the acquisition of Pharmacia Corporation in April 2003. Despite the significant revenue increase, net income declined by 50% to $2.33 billion, or $0.30 per diluted share, from $4.67 billion, or $0.76 per diluted share, in the prior year. This decline is largely attributable to a substantial increase in merger-related expenses, including in-process R&D charges for the Esperion acquisition, and integration/restructuring costs associated with the Pharmacia integration. The company's financial position remains robust with total assets growing to $122.29 billion. However, the balance sheet reflects significant goodwill ($24.26 billion) and identifiable intangible assets ($35.19 billion) stemming from acquisitions. While cash flows from operations were down year-over-year, the company maintained significant liquidity and continued to return capital to shareholders through dividends and share repurchases. Investors should monitor the impact of ongoing restructuring efforts and the performance of recently acquired entities.
Key Highlights
- 1Revenue surged 47% year-over-year to $12.49 billion, largely due to the inclusion of Pharmacia's results post-acquisition.
- 2Net income decreased by 50% to $2.33 billion, impacted by significant merger-related expenses and acquisition charges.
- 3Diluted Earnings Per Share (EPS) fell to $0.30 from $0.76 in the prior year's quarter.
- 4The acquisition of Esperion Therapeutics for $1.3 billion was completed, contributing $920 million in in-process R&D charges.
- 5Significant merger-related costs, including integration and restructuring, amounted to $247 million expensed and $1.1 billion capitalized in the quarter.
- 6Goodwill increased to $24.26 billion, reflecting substantial acquisitions.
- 7The company repurchased $912 million of its common stock in the quarter and declared a $.17 per share dividend.